Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 30 versus DIVALPROEX SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 30 versus DIVALPROEX SODIUM.
DILANTIN-30 vs DIVALPROEX SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium channel inactivation, thereby inhibiting repetitive firing of action potentials.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
300 mg/day orally in 3 divided doses (100 mg three times daily) or 300 mg/day once daily as an extended-release capsule. Loading dose: 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) given at 2-hour intervals. Intravenous fosphenytoin loading dose: 15-20 mg PE/kg; maintenance: 4-6 mg PE/kg/day IV.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life averages 22 hours (range 7–42 hours) in adults; dose-dependent due to saturable metabolism (Michaelis-Menten kinetics). At low concentrations, half-life is approximately 10–15 hours; at high concentrations, half-life may exceed 30 hours. Clinical context: steady state achieved in 5–10 days; half-life prolonged in neonates, elderly, and hepatic impairment.
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
Renal: ~70% (primarily as inactive metabolites including p-HPPH glucuronide, with <5% unchanged); Biliary/fecal: ~30% (enterohepatic circulation contributes to biliary excretion of metabolites and a small amount of unchanged drug).
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Category C
Category D/X
Anticonvulsant
Anticonvulsant